
Catherine Sermet

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12011288/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Services Research, 2010, 10, 153.	0.9	201
2	Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 707-722.	0.7	131
3	Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?. Expert Review of Clinical Pharmacology, 2015, 8, 77-94.	1.3	108
4	Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Frontiers in Pharmacology, 2014, 5, 106.	1.6	107
5	Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets. Frontiers in Public Health, 2018, 6, 328.	1.3	102
6	Ongoing pharmaceutical reforms in France. Applied Health Economics and Health Policy, 2010, 8, 7-24.	1.0	97
7	Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications. Frontiers in Pharmacology, 2010, 1, 141.	1.6	90
8	Personalizing health care: feasibility and future implications. BMC Medicine, 2013, 11, 179.	2.3	81
9	Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?. Pharmaceuticals, 2010, 3, 2470-2494.	1.7	76
10	Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 2013, 4, 39.	1.6	75
11	Trends in Antimicrobial Drug Use in the Community—France, 1981–1992. Journal of Infectious Diseases, 1998, 177, 492-497.	1.9	73
12	Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review. Pharmacoeconomics, 2015, 33, 905-924.	1.7	72
13	Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways. Frontiers in Pharmacology, 2016, 7, 305.	1.6	48
14	Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs. Frontiers in Pharmacology, 2014, 5, 109.	1.6	44
15	Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation. Frontiers in Pharmacology, 2017, 8, 497.	1.6	34
16	European payer initiatives to reduce prescribing costs through use of generics. GaBI Journal, 2012, 1, 22-27.	0.4	32
17	Inégalités de santé liées à l'immigration en France. Revue Economique, 2009, Vol. 60, 385-411.	0.1	28
18	No significant decrease in antibiotic use from 1992 to 2000, in the French community. Journal of Antimicrobial Chemotherapy, 2004, 54, 524-528.	1.3	27

2

CATHERINE SERMET

#	Article	IF	CITATIONS
19	Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future. Frontiers in Pharmacology, 2016, 7, 197.	1.6	26
20	La morbidite dans les menages originaires du Maghreb. Sur la base de l'enquete Sante de l'Insee, 1991-1992. Population, 1998, 53, 1155.	0.1	17
21	Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: A time-series analysis for France 1998–2010. Health Policy, 2011, 102, 159-169.	1.4	11
22	Multilevel Analysis of the Influence of Patients' and General Practitioners' Characteristics on Patented Versus Multiple-Sourced Statin Prescribing in France. Applied Health Economics and Health Policy, 2013, 11, 205-218.	1.0	11